B
oron neutron capture therapy (BNCT) was introduced in 1960's, but showed little development, as the thermal and epithermal neutron sources were not economical. Nuclear reactors, and recently cyclotrons are being used as neutron sources, thus enabling its widespread utilization (1) . Gamma rays are utilized for the irradiation of tumor tissues, and fractional doses up to 50-60 Gray required for tumor ablation in conventional radiation therapy. Such high doses naturally irradiate healthy tissues, and thus result in healthy tissue injury. BNCT was proposed to abolish the side effects of conventional radiation therapy, and basically is a reaction that consists of, targeted of He +2.79MeV (6.3%)). The resulting lithium ions and particles are high linear energy transfer (LET) particles, which produce considerable biological effects. Their short range in tissue (5-9 mm) restricts radiation damage to those cells in which boron atoms are located at the time of neutron irradiation (2). Boron phenyl alanine (BPA), sodium boronocaptate (BSH), and the molecule our team works on, namely BoronoDeoxy-D-Glucose (BDG) are being used for the targeting of boron into the tumor tissue. BCNT was primarily intended to be utilized for the treatment of neck and head cancers due to the technical difficulties and economically burden. Technical improvements in BNCT application has led to consideration of this technique in soft tissue tumors such as breast cancer (3) . Breast cancer is the most common cancer among females, and particularly recurrent breast cancers (RBC) are threatening for women. Radiation therapy is commonly the preferred method of treatment, but has some side effects and insufficient effects against RBC. Recently, BNCT comes to the fore as an alternative approach to therapy. Successful in vitro and simulation studies has led scientists to anticipate successful clinical results in the near future (4, 5 
